Comparative Pharmacology
Head-to-head clinical analysis: CHLOROPTIC S O P versus MUPIROCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLOROPTIC S O P versus MUPIROCIN.
CHLOROPTIC S.O.P. vs MUPIROCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chloramphenicol inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation.
Mupirocin reversibly binds to bacterial isoleucyl-tRNA synthetase, inhibiting protein synthesis.
Apply 0.5-inch ribbon into the conjunctival sac(s) 1-2 times daily, or more frequently as directed.
Apply a small amount of 2% ointment or cream to affected area three times daily for 5 to 14 days.
None Documented
None Documented
Terminal half-life approximately 4-6 hours; clinical context: dosing every 4-6 hours for ocular infections
Clinical Note
moderateMupirocin + Picosulfuric acid
"The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Mupirocin."
Intravenous: ~30 min (0.5 h). Topical: systemically absorbed amount negligible, local half-life not defined.
Renal (70-80% as unchanged drug and metabolites), biliary/fecal (20-30%)
Renal: <1% unchanged (topical); hepatic metabolism to monic acid, eliminated renally and fecally. After IV administration, 60-70% renal, 20-30% fecal/biliary.
Category C
Category A/B
Antibiotic
Antibiotic